QIAGEN has secured a new contract from the US Government to boost production capacity for Covid-19 tests running on NeuMoDx instruments. The $3.4m contract was awarded by the Department of Defense (DoD). Under the contract, QIAGEN will increase production of PCR tests for NeuMoDx 96 and 288 clinical integrated systems at its site in Michigan. The company aims to ramp up production by the end of March 2022 from 10 million tests a year to more than 16 million.